Trial Profile
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Nofazinlimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Leiomyosarcoma; Liver cancer; Lymphoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors CStone Pharmaceuticals
- 28 Nov 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 19 May 2022 Planned End Date changed from 31 Mar 2022 to 30 Sep 2022.